Alzheimer’s Disease: A Field in Transformation

Symphony Care Management - Alzheimer's Disease - A Field in Transition

Julia Nickrosz, CDP, Aging Life Care Manager, Dementia Specialist

Because June is Alzheimer’s Awareness & Brain Health Month, it is important to recognize one of the most significant shifts in modern medicine: Alzheimer’s disease is no longer viewed as untreatable or hopeless. For decades, a diagnosis largely meant progressive decline with limited options beyond symptom management and supportive care. Today, the field is entering a fundamentally different era, one focused on earlier detection, disease-modifying treatments, genetic risk awareness, and prevention-oriented research.

I. Where we stand today

  1. A Deeper Understanding of What Alzheimer’s Really Is

One of the biggest changes is how we understand  the biology of the disease. Alzheimer’s is no longer seen as a disease caused by just one thing. Instead, it is now understood as a slow process involving several changes in the brain that build up over many years, often decades before symptoms like memory loss appear.

This process involves several changes in the brain that build up over time. Sticky protein buildup called amyloid forms plaques, another protein called tau spreads through brain cells, and there can also be ongoing inflammation, changes in blood flow, shifts in how the brain uses energy, and gradual loss of connections between brain cells.

This matters because it changes how we think about treatment. If Alzheimer’s develops slowly over many years and involves multiple processes, then waiting until memory problems appear means much of the damage has already been happening in the background for a long time.

  1. Alzheimer’s Disease – Shift From Treating Symptoms to Slowing The Disease

For a long time, treatment existed almost entirely at the symptom level.

Medications such as Aricept (donepezil) and Namenda (memantine) helped support memory, attention, and daily functioning. For many families, they provided meaningful stability but they did not slow disease progression.

That limitation of previous treatments is what makes the current era different. With lecanemab (Leqembi) and donanemab (Kisunla), medicine has entered the first generation of disease-modifying Alzheimer’s therapies. These drugs target amyloid accumulation directly, helping reduce plaque burden in the brain.

The benefit is measured but important: a modest slowing of cognitive and functional decline in early-stage disease. In practical terms, that may mean more time with preserved independence, communication, and quality of life before more advanced decline occurs.

The significance is less about magnitude and more about direction, it is the first time treatment has been shown to alter the underlying biology of Alzheimer’s itself. But the true weight of that impact is something only fully understood by the person living it, and those walking alongside them day to day.

  1. Risk Becomes More Individualized, Not Generalized

As new treatments for Alzheimer’s disease have emerged, so has a more detailed understanding of their risks. Risk is no longer viewed in a simple, generalized way, Instead, it is now understood as something that varies from person to person and can be carefully monitored.

One important risk to be aware of is called ARIA (amyloid-related imaging abnormalities). They include temporary swelling (ARIA-E) or tiny microbleeds (ARIA-H). In the CLARITY-AD trial, ARIA occurred in about 12–13% of all participants, but most cases were asymptomatic, detected only on routine MRI, and resolved with monitoring or temporary treatment pauses. Serious symptomatic cases were uncommon, occurring in about ~2–3% of treated participants.

Risk is not evenly distributed. APOE4 status is the strongest known risk factor:

  • Non-carriers: ~5–10% ARIA
  • One APOE4 copy: ~10–20% ARIA
  • Two APOE4 copies: ~25–35% ARIA

Even in higher-risk groups, most ARIA findings were seen only on MRI without symptoms, and severe complications remained rare under careful monitoring.

One important nuance often lost in public discussion is that terms like “brain swelling” or “brain bleeding” can sound frightening, but in Alzheimer’s trials they usually refer to small, temporary MRI changes, not the severe bleeding people often imagine. Knowledge is power, it helps replace fear with context from the actual data.

This is why Alzheimer’s specialists emphasize the full clinical picture genetics, disease stage, MRI surveillance, and treatment goals rather than isolated percentages, which can sound more alarming without context.

This has shifted decision- about treatment options from a simple safety question to a more individualized one: for which patient, at what stage, and under what monitoring does benefit outweigh risk?

  1. Clinical Interpretation and the Role of Expertise

Another layer is that risk is often interpreted differently depending on experience. Clinicians who don’t use these therapies regularly may understandably focus more on potential risks based on trial data, while specialized memory centers are also drawing on real-world experience, MRI monitoring, and day-to-day management of patients on treatment. This is why seeing a Cognitive Neurologist who is actively overseeing infusions at a specialized Alzheimer’s center can be helpful. It is not that the data changes, but that experience can change how it’s applied to an individual person.

At its core, Alzheimer’s care comes down to balancing three things: what the science shows, what clinicians are seeing in practice, and what a person and family feel is the right course for their own life and goals.

II. Where Are We Heading – The Pipeline: A Shift Beyond Amyloid Alone

While current treatments focus primarily on amyloid, the research landscape has already moved further. It is now widely recognized that Alzheimer’s involves multiple interacting systems, which is why current clinical trials are targeting several pathways simultaneously:

  • amyloid processing
  • tau aggregation and spread
  • neuroinflammation and immune signaling
  • vascular integrity and blood flow
  • synaptic function and neuronal resilience

1. Therapies In Trial- Stage 2 and 3:

a. Stage 3:

  • Remternetug – a next-generation amyloid antibody designed for faster plaque clearance
  • Trontinemab – engineered to improve brain penetration and potentially reduce side effects
  • ALZ-801 – an oral therapy targeting toxic amyloid oligomers earlier in the disease cascade
  • Buntanetap – a multi-target approach affecting amyloid, tau, and alpha-synuclein
  • AR-1001 – focused on neuronal signaling and synaptic preservation rather than plaque removal alone

Alongside these  Phase 2 programs such as semorinemab and E2814 target tau pathology and neurodegenerative spread more directly.

The significance is not any single drug, but the direction: Alzheimer’s is becoming a multi-pathway treatment field.

  1. Combination Therapy as the Emerging Model

Alzheimer’s disease doesn’t come from one simple cause, it involves several interconnected biological processes happening in the brain at the same time. Due to this, there is growing agreement in the field that no single treatment is likely to be enough on its own.

Instead, Alzheimer’s is moving toward a combination model similar to other complex diseases such as cancer, HIV, and cardiovascular disease. Future treatment is likely to involve layered approaches that target: amyloid removal, tau spread, inflammation, and neuronal support simultaneously.

This is not hypothetical in concept anymore; it is the direction of active trial design.

  1. Early Detection: A Structural Shift in Medicine

One of the most important shifts in Alzheimer’s research is moving toward identifying the disease before symptoms appear. The AHEAD Study (led by Mass General Brigham and other academic centers) is exploring whether treating amyloid in people who are still cognitively normal, but already show early biological signs of Alzheimer’s, can delay or even prevent future decline.

This reflects a major change in medicine: Alzheimer’s is increasingly being defined not only by symptoms, but by what is happening biologically in the brain long before those symptoms begin.

Emerging tools such as blood-based biomarkers, PET imaging, and genetic testing (including APOE4) are making it possible to identify risk years earlier than clinical diagnosis.

Amyloid is expected to be the first biomarker widely used in practice because it is already the main target of current therapies. Blood-based amyloid tests are likely to enter specialty care within the next 2–5 years (2026–2030), improving early identification and access to treatment. If prevention trials like AHEAD are successful, pre-symptomatic treatment approaches could begin emerging in the early-to-mid 2030s, especially for higher-risk individuals.

  1. Changing the Meaning of a Diagnosis

Even just a few years ago, an Alzheimer’s diagnosis often felt like a final answer. While the disease is still incurable and remains very serious, that sense of finality is starting to change. Today, Alzheimer’s is treatable, we can slow progression.  A diagnosis is now the beginning of a path, one that includes closer monitoring, opportunities for earlier treatment, access to clinical trials, and a growing range of treatment possibilities that did not exist before.  For many families, that does not remove fear, but it changes its shape. Uncertainty still exists, but it is no longer paired with the same sense of complete clinical plateau. Earlier detection only becomes meaningful when there are real options to act on it and that is now beginning to change.

  1. Looking Ahead: How This Will Likely Evolve

Looking forward, the evolution is likely to occur in stages. In the near term (2026–2028), progress will likely center on single-agent therapies such as next-generation amyloid antibodies, improved brain-penetrant drugs, and early oral interventions, each refined by biomarker-guided selection.

Between 2028 and 2032, if current trials succeed, the field is expected to shift toward true combination regimens, layering amyloid, tau, and inflammation-targeted therapies in more personalized sequences.

By the 2030s, Alzheimer’s care may begin to resemble other chronic disease models, adaptive, biomarker-guided, and long-term therapies where treatment is adjusted over time rather than defined by a single static plan.

Julia’s Note to Families Living with Alzheimer’s

Alzheimer’s Disease remains a complex and serious disease. There is no cure, and progress is still incremental. Unlike in the past, Alzheimer’s research is not at a standstill anymore. We now understand much more about what causes the disease, we can identify it earlier, and we finally have treatments that can make a real difference for some people.

These treatments are not cures, and the effects are still modest, but they slow disease progression and help preserve daily function and quality of life for a longer period of time.

With additional therapies in development and a rapidly advancing research pipeline, there is HOPE that the treatment landscape will continue to expand over the coming years. For people who are newly diagnosed today, and for future generations, the trajectory of Alzheimer’s care is no longer at a standstill, it is evolving.

After many years with very limited options, even incremental improvements are starting to matter in practical ways for families: more time with independence, more stability in early stages, and more tools for clinicians to tailor care to the individual rather than relying on a one-size-fits-all approach.

If you are diagnosed today, this is what I want you to know: This is not the end of your story. And you are not facing this alone.

  • The reality ofAlzheimer’s disease today is different than it was even a decade ago. We understand more about the disease, we can identify it earlier, and we now have treatments and strategies that can slow progression for some people and help preserve independence and daily life for longer.
  • There is real support available, medical care, treatment options, lifestyle approaches, and resources for both patients and families. Some of these may feel small on their own, but together they can make a meaningful difference in day-to-day life and long-term function.
  • You don’t have to figure any of this out at once. There is time to plan, time to adjust, and time to choose what feels right for you.
  • We stand with you in this. Whether that means exploring treatment, building supportive routines, focusing on brain and body health, or simply helping you find your footing after the diagnosis, you will have help along the way.
  • If there is a silver lining, it is this: You are not at the end, you are at the beginning of a new path where there is support, treatment options that can slow disease progression, a rapidly evolving pipeline of new therapies, and a community of specialists, researchers, clinicians, and caregivers committed to walking this journey with you.

Call to Action

We will be walking in the 2026 Walk to End Alzheimer’s Disease, and we invite you to stand with us and support this mission.

There is support, there are options, and there are real people committed to walking this path with you.

We walk for our clients, and for the families who are navigating this every single day. We walk for our own loved ones who have been through this journey and have shown us what it truly looks like up close.

We walk for families in the “sandwich generation,” balancing the care of aging parents while raising children, all while carrying the uncertainty of what their own future may hold.

We walk for knowledge, because understanding the brain and the disease more deeply leads to better care, earlier support, and better decisions. We walk for research, because every step forward brings us closer to more effective treatments and, one day, prevention.

We walk for hope, not as something abstract, but as something real, grounded in scientific progress happening right now.

We walk for the future: for those who are newly diagnosed today, and for those who may be diagnosed years or decades from now, with the hope that earlier detection and pre-symptomatic treatment will become a reality in a meaningful, practical way that benefits the next generation.

We walk so no one faces this alone. Even in Alzheimer’s, there is still a connection. Still support. Still dignity. Still life. There is life after diagnosis and it can still be meaningful. We walk for today, for tomorrow, for each other.

The Symphony Care Management Team will be walking in October, 2026. We are inviting our friends and families – and we hope you will join us. More information coming soon!

LEARN MORE: Trusted Resources for Families

For families and individuals wanting to better understand Alzheimer’s disease, treatments, and current research, the following trusted resources provide clear, accessible information:

  • National Institute on Aging (NIH) – Alzheimer’s Disease Information
    https://www.nia.nih.gov/health/alzheimers
    A trusted government resource covering disease basics, early detection, research updates, and biomarker science in simple language.

REFERENCES:

  1. van Dyck, C.H., et al. (2022). Lecanemab in Early Alzheimer’s Disease (CLARITY-AD). NEJM. https://doi.org/10.1056/NEJMoa2212948

  2. Jack, C.R., et al. (2018). NIA-AA Biological Framework. Alzheimer’s & Dementia. https://doi.org/10.1016/j.jalz.2018.02.018

  3. De Strooper, B. & Karran, E. (2016). Cellular Phase of Alzheimer’s Disease. Cell. https://doi.org/10.1016/j.cell.2015.12.056

  4. Sims, J.R., et al. (2023). Donanemab Phase 3 Trial. JAMA. https://doi.org/10.1001/jama.2023.13239

  5. Cummings, J., et al. (2023). ARIA Appropriate Use Recommendations. Journal of Prevention of Alzheimer’s Disease. https://doi.org/10.14283/jpad.2023.30

  6. Qi, L., et al. (2026). Meta-analysis of anti-amyloid therapies and ARIA risk. Journal of Prevention of Alzheimer’s Disease.

  7. Cummings, J., et al. (2024). Alzheimer’s Drug Development Pipeline Update. Alzheimer’s & Dementia: TRCI.

  8. Alzheon / ALZ-801 APOE4 Phase 3 updates (2025–2026 clinical program publications).